Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Certain Genes Could Indicate Infection Resistance, Suggests Study

By Drug Discovery Trends Editor | January 25, 2016

Scientists from Duke University conducted a study to see how individuals’ DNA might impact their probability of contracting a common bacterial infection from E. coli bacteria. 

The researchers administered the bacterium to 30 volunteers, according to the study published in the Journal of Infectious Diseases. E. coli can cause diarrhea, but six participants displayed no symptoms, while another six succumbed to the infection over a period of eight days.

Next, the team took blood samples from all participants to identify certain forms of gene expression. A comparison was done between patients with severe symptoms to patients with minimal symptoms. The analysis showed there were substantial alterations in 29 genes related to immune function.

These specific genes may have been activated with the bacterium’s presence, but it was unclear if that was the reason for the strong immune response or if it was due to mutations in the genes of patients with few symptoms, reports Popular Science.

Still, the scientists believe this could improve predictions for which patients may have a strong reaction to E. coli bacteria.

You can read the rest of the research published in the Journal of Infectious Diseases.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50